Female patients with ankylosing spondylitis: Analysis of the impact of gender across treatment studies

Annals of the Rheumatic Diseases

Volumn 72, Issue 7, 2013, Pages 1221-1224

  Van Der Horst Bruinsma, Irene E ^a   Zack, Debra Jeske ^b   Szumski, Annette ^c   Koenig, Andrew S ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AMGEN INC   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; HLA B27 ANTIGEN; PLACEBO; SALAZOSULFAPYRIDINE;

ADULT; AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS; ARTICLE; BACKACHE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DEMOGRAPHY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; UVEITIS;

ANKYLOSING SPONDYLITIS; ANTI-TNF; DMARDS (BIOLOGIC); TREATMENT;

ADULT; ANTIRHEUMATIC AGENTS; C-REACTIVE PROTEIN; CONTROLLED CLINICAL TRIALS AS TOPIC; FEMALE; HLA-B27 ANTIGEN; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SPONDYLITIS, ANKYLOSING; SULFASALAZINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878409490     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202431     Document Type: Article

References (26)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369:1379-90. (Pubitemid 46590387)
2. Davis JC, van der Heijde D, Dougados M, et al. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005;53:494-501. (Pubitemid 41278913)
3. Zink A, Braun J, Listing J, et al. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000;27:613-22. (Pubitemid 30151336)
4. Polley HF, Slocumb CH. Rheumatoid spondylitis: a study of 1,035 cases. Ann Intern Med 1947;26:240-9.
5. West HF. Aetiology of ankylosing spondylitis. Ann Rheum Dis 1949;8:143-8.
6. Calin A, Elswood J, Rigg S, et al. Ankylosing spondylitis-an analytical review of 1500 patients: the changing pattern of disease. J Rheumatol 1988;15:1234-8.
7. Carbone LD, Cooper C, Michet CJ, et al. Ankylosing spondylitis in Rochester, Minnesota, 1935-1989. Is the epidemiology changing? Arthritis Rheum 1992;35:1476-82. (Pubitemid 23013655)
8. Gran JT, Ostensen M, Husby G. A clinical comparison between males and females with ankylosing spondylitis. J Rheumatol 1985;12:126-9. (Pubitemid 15131442)
9. Hill HF, Hill AG, Bodmer JG. Clinical diagnosis of ankylosing spondylitis in women and relation to presence of HLA-B27. Ann Rheum Dis 1976;35:267-70.
10. Kennedy LG, Will R, Calin A. Sex ratio in the spondyloarthropathies and its relationship to phenotypic expression, mode of inheritance and age at onset. J Rheumatol 1993;20:1900-4. (Pubitemid 24031595)
11. Masi AT, Wilkins WR. Does male:female sex ratio in ankylosing spondylitis change with age? J Rheumatol 1996;23:947-8.
12. Will R, Edmunds L, Elswood J, et al. Is there sexual inequality in ankylosing spondylitis? A study of 498 women and 1202 men. J Rheumatol 1990;17:1649-52.
13. Lee W, Reveille JD, Weisman MH. Women with ankylosing spondylitis: a review. Arthritis Rheum 2008;59:449-54. (Pubitemid 351399217)
14. Lee W, Reveille JD, Davis JC Jr, et al. Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis 2007;66:633-8. (Pubitemid 46707132)
15. Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical effi cacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011;63:1543-51.
16. Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600. (Pubitemid 39573687)
17. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6. (Pubitemid 37409337)
18. van der Heijde D, Da Silva JC, Dougados M, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:1572-7. (Pubitemid 44799667)
19. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8. (Pubitemid 14134775)
20. Ward MM. Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol 2002;29:1420-5. (Pubitemid 34755608)
21. Ward MM, Kuzis S. Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol 2001;28:315-21. (Pubitemid 32165140)
22. Ward MM, Weisman MH, Davis JC Jr, et al. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum 2005;53:710-17. (Pubitemid 41463836)
23. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
24. Cheung PP, Paternotte S, Burki V, et al. Performance of the assessment in Spondyloarthritis International Society classification for axial and peripheral spondyloarthritis in an established clinical cohort: comparison with criteria sets of amor and the European Spondylarthropathy Study Group. J Rheumatol 2012;39:816-21.
25. Strangfeld A, Listing J. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res 2006;20:1181-95. (Pubitemid 44774817)
26. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract 2006;2:602-10. (Pubitemid 44650948)